Literature DB >> 34076618

Cost analyses of HIV treatment should be standardized and report cost drivers.

Arielle Lasry1, Madeleine Baker-Goering.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34076618      PMCID： PMC9341127          DOI： 10.1097/QAD.0000000000002931

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.632


× No keyword cloud information.
  4 in total

1.  Global estimates for the lifetime cost of managing HIV.

Authors:  Huynh Tran; Kanwal Saleem; Megumi Lim; Eric P F Chow; Christopher K Fairley; Fern Terris-Prestholt; Jason J Ong
Journal:  AIDS       Date:  2021-07-01       Impact factor: 4.177

2.  Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.

Authors:  Rochelle P Walensky; Paul E Sax; Yoriko M Nakamura; Milton C Weinstein; Pamela P Pei; Kenneth A Freedberg; A David Paltiel; Bruce R Schackman
Journal:  Ann Intern Med       Date:  2013-01-15       Impact factor: 25.391

Review 3.  Long-acting drugs and formulations for the treatment and prevention of HIV infection.

Authors:  Charles Flexner; Andrew Owen; Marco Siccardi; Susan Swindells
Journal:  Int J Antimicrob Agents       Date:  2020-11-06       Impact factor: 5.283

4.  S4HARA: System for HIV/AIDS resource allocation.

Authors:  Arielle Lasry; Michael W Carter; Gregory S Zaric
Journal:  Cost Eff Resour Alloc       Date:  2008-03-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.